INCIPIT technology allowed the implementation of a multifunctional, micro-structured and electroconductive therapeutic product to treat patients with myocardial infarction, the leading cause of death for cardiovascular disease. Current therapies (drugs, bypass, angioplasty) do not restore the functionality of damaged myocardial tissue.
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 5 of 5
The herein described technology aims at the development of a platform of injectable hydrogels for application as drug carriers for localized delivery or in the regenerative medicine field. The use of ad-hoc synthesized poly(ether urethane)s (PEUs) as hydrogel forming materials is a common property which characterizes all the systems belonging to this platform.
An innovative approach for the treatment of diabetic and venous ulcers, characterized by a difficult healing process and therefore at potential risk of infection and therefore of hospitalization and amputation of the limb, is represented by the local administration of "bioactive" factors through the use of synthetic and/or biological matrices that allow a gradual and controlled release in order to obtain a better and faster healing.
Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules:
Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.